GPT and fatty liver disease: Interestingly, HF-HC DMM-treated mice presented a significant reduction of cellular damage, as shown by ALT serum levels (Figure 7B) and lower hepatic steatosis (Figures 7C and 7D), compared to vehicle-treated mice, although with no significant change in body weight or liver/body weight ratio (Figures 7E and 7F).